C
25.38
0.53 (2.13%)
| Previous Close | 24.85 |
| Open | 25.08 |
| Volume | 875,340 |
| Avg. Volume (3M) | 1,579,604 |
| Market Cap | 3,751,669,760 |
| Price / Sales | 197.93 |
| Price / Book | 8.96 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -205.18% |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 30.55% |
| Current Ratio (MRQ) | 14.37 |
| Operating Cash Flow (TTM) | -162.02 M |
| Levered Free Cash Flow (TTM) | -106.95 M |
| Return on Assets (TTM) | -28.58% |
| Return on Equity (TTM) | -74.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Centessa Pharmaceuticals plc | Bearish | Bullish |
AIStockmoo Score
1.8
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.75 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 94.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Index Venture Life Associates Vi Ltd | 30 Sep 2025 | 9,961,789 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 62.00 (Oppenheimer, 144.29%) | Buy |
| Median | 40.00 (57.60%) | |
| Low | 30.00 (Chardan Capital, 18.20%) | Buy |
| Average | 42.40 (67.06%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 26.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 24 Feb 2026 | 40.00 (57.60%) | Buy | 26.23 |
| Truist Securities | 29 Jan 2026 | 38.00 (49.72%) | Buy | 24.89 |
| 08 Jan 2026 | 33.00 (30.02%) | Buy | 22.05 | |
| Chardan Capital | 02 Jan 2026 | 30.00 (18.20%) | Buy | 23.69 |
| Oppenheimer | 10 Dec 2025 | 62.00 (144.29%) | Buy | 29.57 |
| B. Riley Securities | 01 Dec 2025 | 42.00 (65.48%) | Buy | 28.47 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |